ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 25 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 50 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - sildenafil as citrate - טבליות מצופות פילם - sildenafil as citrate 100 mg - sildenafil - sildenafil - treatment of erectile dysfunction.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - phenoxybenzamine hydrochloride - קפסולות - phenoxybenzamine hydrochloride 10 mg - phenoxybenzamine - phenoxybenzamine - pheochromocytoma, benign prostatic hypertrophy.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - apixaban - טבליות מצופות פילם - apixaban 2.5 mg - apixaban - apixaban - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age? 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ? ii).